Nano-enabled Drugs
Aura™ Biosciences is pioneering the development of nano-enabled drugs through its proprietary Nanosmart™ platform. Nanosmart solves critical issues in drug delivery by encapsulating therapies within protein nanoparticles engineered for precise targeting, immune system evasion, and efficient cellular uptake. With a uniform structure and reproducible distribution of surface targeting molecules, Nanosmart proteins also offer scalable manufacturing.
Aura’s initial focus is on applying Nanosmart to the treatment of pancreatic cancer, a disease that kills 95% of patients within just five years. Nanosmart-enabled chemotherapy is designed to be more effective and better tolerated, allowing more patients to be treated and to help improve survival of this devastating disease.
More >>
World Class Scientific and Business Advisors Join Aura Biosciences
Aura Biosciences Press Release
Aura CEO, Elisabet de los Pinos, PhD, to speak at Convergence: The Life Sciences Leaders Forum
Newport, June 11-13
New deal boosts development of targeting peptides in nanotechnology
Cancer Research Technology Ltd. Press Release
Aura Biosciences Aims to Develop “Ballistic-missile” Drug
By Ryan McBride, Xconomy
Copyright © AURA™ Biosciences, Inc. All Rights Reserved.